PCSK9 and acute coronary syndrome: There are several recent or ongoing studies examining the early use of PCSK9 inhibitors in acute coronary syndrome patients undergoing percutaneous coronary intervention with anticipated extra-LDL reduction and other pleiotropic effects (15, 26, 27).